Medico Intercontinental Limited

539938

INE858Q01019

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 10:30:49 30/05/2024 am IST			5-day change	1st Jan Change
46.9 ^INR	+2.33%		+1.23%	-49.54%

25/05	Medico Intercontinental Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
25/05	Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Medico Intercontinental Limited Approves Regularisation of Nikul Dipakbhai Shah as an Independent Director

September 28, 2022 at 04:07 pm IST

Medico Intercontinental Limited at the AGM, the shareholder approved regularisation of Mr. Nikul Dipakbhai Shah as an Independent Director.

Latest news about Medico Intercontinental Limited

Medico Intercontinental Limited Reports Earnings Results for the Full Year Ended March 31, 2024	25/05	CI
Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	25/05	CI
Medico Intercontinental Limited Announces Resignation of Nikul Dipakbhai Shah as Independent Director	25/04	CI
Medico Intercontinental Limited Proposes to Incorporate Joint Venture Partnership Firm	09/04	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11	CI
Medico Intercontinental Limited Approves Final Equity Dividend for the Financial Year 2022-23	30/23/30	CI
Medico Intercontinental Limited Approves the Regularisation of Priyank Lalitbhai Sancheti as an Independent Director	30/23/30	CI
Medico Intercontinental Limited Reports Earnings Results for the Full Year Ended March 31, 2023	06/23/06	CI
Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	29/23/29	CI
Medico Intercontinental Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable on or After July 5, 2023	29/23/29	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
Medico Intercontinental Limited Appoints Priyank L Sancheti as an Additional Independent Director	14/22/14	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/22/14	CI
Medico Intercontinental Limited Approves Regularisation of Nikul Dipakbhai Shah as an Independent Director	28/22/28	CI
Medico Intercontinental Limited announced that it expects to receive INR 249.787 million in funding	27/22/27	CI
Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	13/22/13	CI
Medico Intercontinental Limited Announces Resignation Mr. Hiren Ravindrabhai Shah as Independent Director	30/22/30	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/22/14	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	12/21/12	CI
Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	14/21/14	CI
Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	29/21/29	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/21/12	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	14/20/14	CI
Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	15/20/15	CI

Chart Medico Intercontinental Limited

Duration

Period

More charts

Medico Intercontinental Ltd is engaged in the business of trading of pharmaceutical products. It provides platform to all research-based biopharmaceutical companies. Its product categories include gastro, uro, nutrition, cosmetology, health devices, hospital, and other areas. Its products include ACIFACT-BLI, ACIFACT-P, ACIFACT-SP (ALU-ALU), ALBECTIN, ALFACARE - D3, ARSUFACT Combokit, BALOFACT, CYCLOFACT 400, UDIFACT 150, XOFACT - 4, ZIFT SL - 250, ZYMIX, ARGIFACT, CLIANCIACT POWDER, RELIEVE CZ, VOLIREX SPRAY, RACIMAX SACHET, PERMACT, OROFACT, KTZ, FEMYACT, LIVOFACT, ZYMIX SY, ULTRATONE SY, ALBECTIN SUS, BECOFACT DROPS, MEFACT P SUS, ONCARE SOLUTION, OFCARE-FORTE SUS, PRODOM CV SY., RELIBEN SUSP., ZIFT SUSP.-200 MGCIPACT EYE DROP, OROFACT-PASTE(lamy), OROFACT MOUTH ULCER GEL, CALAMED LOTION and others. Its subsidiaries include Evagrace Pharma Private Limited, Ritz Formulations Private Limited, Sungrace Pharma Private Limited, and Azillian Healthcare Private Limited.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MEDICO INTERCONTINENTAL LIMITED	-49.54%	54.98L
SUN PHARMACEUTICAL INDUSTRIES LTD.	+16.21%	4.26TCr
OTSUKA HOLDINGS CO., LTD.	+17.51%	2.1TCr
SANDOZ GROUP AG	+16.67%	1.49TCr
CIPLA LIMITED	+18.65%	1.45TCr
ZYDUS LIFESCIENCES LIMITED	+50.52%	1.26TCr
THE MEDICINES COMPANY	-0.05%	678.76Cr
ONO PHARMACEUTICAL CO., LTD.	-11.96%	657Cr
STADA ARZNEIMITTEL	-8.87%	572.55Cr
ASPEN PHARMACARE HOLDINGS LIMITED	+14.28%	562.47Cr